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Abstract
We have shown that intravenous immunoglobulin (IVIG) contains anti-Aβ autoantibodies and
IVIG could induce beta amyloid (Aβ) efflux from cerebrospinal fluid (CSF) to blood in both
Multiple Sclerosis (MS) and Alzheimer disease (AD) patients. However, the molecular
mechanism underlying IVIG-induced Aβ efflux remains unclear. In this study, we used amyloid
precursor protein (AβPP) transgenic mice to investigate if the IVIG could induce efflux of Aβ
from the brain and whether low-density lipoprotein receptor-related protein-1 (LRP1), a
hypothetic Aβ transporter in blood-cerebrospinal fluid barrier (BCB); could mediate this clearance
process. We currently provide strong evidence to demonstrate that IVIG could reduce brain Aβ
levels by pulling Aβ into the blood system in AβPP transgenic mice. In the mechanistic study,
IVIG could induce Aβ efflux through the in-vitro BCB membrane formed by cultured BCB
epithelial cells. Both RAP (receptor-associated protein; a functional inhibitor of LRP1), and LRP1
siRNA were able to significantly inhibit the Aβ efflux. Should Aβ prove to be the underlying
cause of AD, our results strongly suggest that IVIG could be beneficial in the therapy for
Alzheimer's disease (AD) by inducing efflux of Aβ from the brain through the LRP1 in the BCB.
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Introduction
Alzheimer's disease (AD) is the most common type of dementia in the elderly. Beta-amyloid
(Aβ, a 39-42 amino acid proteolytic product of the amyloid precursor protein) accumulation
in the brains extracellular space is believed to be one of several contributing factor to AD
pathology (Ogomori et al., 1989). Increased levels of Aβ in the brains of AD patients may
result from either the overproduction of Aβ or an inadequate metabolism/clearance within
the brain. It may be a primary event that leads to amyloid plaque deposition and
subsequently to the cascade of other neuropathological changes associated with the disease.
Therefore, various therapeutic approaches are aimed to reduce the amount of Aβ-peptide
including inhibition of β- and γ-secretase activity, inhibition of toxic Aβ fibrillation/
aggregation, and enhancing Aβ clearance (Poduslo et al., 1999, Ghosh et al., 2002).
Recently, it has been shown that immune-mediated clearance pathways may have an
important impact on plaque development in the brain (Schenk et al., 1999, Bard et al., 2000).
It has been suggested that antibodies against Aβ could prevent amyloid deposition,
ameliorate amyloid-mediated behavioral deterioration, and even clear existing plaques
(Janus et al., 2000, Morgan et al., 2000). The Aβ peripheral sink hypothesis was also made
based on the finding that Aβ can be transported out of brain when antibodies were mainly
present in blood (DeMattos et al., 2002). As early as 1980, intravenous immunoglobulin
(IVIG), an immune globulin product from human plasma, was used in the treatment of a
variety of diseases (Fabian, 1980). A substantial amount of research has reported that there
are abundant Aβ autoantibodies in IVIG and these autoantibodies or IVIG may be effective
for the treatment of AD and other neurodegenerative disorders (Dodel et al., 2002, Neff et
al., 2008, Relkin et al., 2009, Dodel et al., 2010). Treatment with IVIG increased both CSF
and serum levels of anti-Aβ antibodies and significantly lowered CSF levels of Aβ in AD
patients, possibly by facilitating transport of Aβ from the CSF to the serum (Dodel et al.,
2002). Most recently, clinical data demonstrated that IVIG treatments may slow down
hypometabolic development in AD brains (Dodel et al., 2010). However, the mechanism
underlying the IVIG-induced brain Aβ efflux/clearance remains to be determined.
The blood-brain barrier (BBB) and blood-cerebrospinal fluid (CSF) barrier (BCB) are two
brain barriers that separate the systemic blood circulation from the brain. The BBB is mainly
composed of tightly connected cerebral capillary endothelial cells and prevents substances
from leaving the blood and crossing the capillary walls into the brain tissues. Unlike the
capillaries that form the BBB, the choroid plexus (CP), located within brain ventricles, tight
junctions between the choroidal epithelial cells that seal one epithelium to another,
constituting the BCB (Smith, 1991) that was thought to regulate efflux of molecules from
CSF into the blood (Brown et al., 2004). It's been reported that Aβ transports across the
BBB into the brain from the systemic circulation via advanced glycation end-products
(RAGE), while out of the brain via the low-density lipoprotein receptor-related protein
(LRP)-1 (Deane et al., 2004, Donahue et al., 2006). Additionally, several studies have also
shown Aβ transports across the BCB (Sasaki et al., 1997, Monro et al., 2002, Serot et al.,
2003, Crossgrove et al., 2005) and presents in the CP of AD patients (Kalaria et al., 1996).
Since the CP is in direct continuity with the cerebral interstitial fluid (ISF) and the CSF, Aβ
in the brains extracellular space can freely enter into the CSF. Immunoreactive Aβ and its
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precursor protein AβPP in the CP (Sasaki et al., 1997, Crossgrove et al., 2007) suggests that
the CP may be involved in the brains Aβ clearance (Crossgrove et al., 2005, Behl et al.,
2009a, Gu et al., 2011). Thus, it is interesting to explore the role of the BCB in the brain Aβ
clearance and IVIG-induced efflux of Aβ from brains.
Low-density lipoprotein receptor-related protein 1 (LRP1) is a member of the LDL receptor
family and has various unrelated functions; it participates in cholesterol and lipid transport,
and plays a role in the clearance of extracellular proteases and proteinase complexes of
apoptotic cells and debris. Aβ binds to alpha-2-macroglobulin (A2M) and apolipoprotein E
(apoE). LRP1 serves as a receptor for these two proteins, and LRP1-mediated clearance of
A2M and apoE contributes to a reduction in Aβ levels (Herz and Strickland, 2001). LRP1
may play a role in the BBB to transfer Aβ from the brain to the blood (Kounnas et al., 1995,
Knauer et al., 1996, Goto and Tanzi, 2002, Moir and Tanzi, 2005, Yamada et al., 2009).
Recently, LRP1 was identified in the CP. Reduced LRP1 expression in the CP following
lead (Pb) treatments may be associated with Pb-induced accumulation of Aβ in brain (Behl
et al., 2009a, Gu et al., 2011). It was suggested that Aβ elimination form CSF was possibly
mediated by LRP1 expressed at the CP (Fujiyoshi et al., 2011). These evidences suggest that
LRP1 may be involved in the IVIG-induced Aβ clearance in the peripheral clearance
system.
While much work has been done in immunization treatments for Alzheimer's disease and a
peripheral sink hypothesis has been proposed extensively, the molecular mechanism
underlying antibody-induced efflux of Aβ from brain remains unclear. To address these
questions, we used AβPP transgenic mice and an in vitro BCB system to investigate whether
IVIG could induce efflux of Aβ from the brain through the BCB and if LRP1 mediated this
process.
Materials and methods
Animals and treatments
An amyloid precursor protein (AβPP) transgenic mouse model overexpressing human AβPP
with a mutation (V717F) that causes an autosomal dominant form of familial AD was
utilized (Gu et al., 2011). In this study, 3 month old mice showed high levels of human Aβ
protein in brains without having plaques, which was consistent to previous reports
demonstrating these mice had an age-related accumulation of Aβ plaques in brains starting
from 6 months of age (Bales et al., 1999). AβPP transgenic mice (AβPP V717F) (on a
C57BL/6 genetic background) were bred in the Animal Center at Indiana University School
of Medicine. Mice were housed 3–5 mice per cage, fed with food and water ad libitum, and
maintained in a 12-h light/dark cycle facility. A group of 3 month old AβPP transgenic mice
(n = 6 per group) were i.v. injected in the lateral tail vein with 500 μg (20mg/kg) IVIG or
IVIG in which anti-Aβ antibodies had been depleted (IVIG w/o anti-Aβ) once a week for
two weeks. Hippocampus, cortex, CSF and plasma samples were collected after two weeks
treatment. Plasma was collected immediately after CSF was collected. Fresh samples were
immediately tested afterward. Animal protocols pertinent to this study were approved by the
Indiana University School of Medicine Laboratory Animal Resource Center.
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Depletion of anti-Aβ antibody from IVIG
The protocol was adapted from a previously described method (Du et al., 2001, Du et al.,
2003). The column was packed with NHS-sepharose 4B (Pharmacia Biotech, Piscataway,
NJ) labeled with Aβ 1-40 (generous gifts from Eli Lilly, Indianapolis, IN, 0.6 mg/ml drained
sepharose) and was equilibrated and washed with PBS (pH 7.4). After passing purified
human IVIG (Bayer, Pittsburgh, PA) through the column, unbound fraction (IVIG w/o anti-
Aβ ) was collected.
Culture of choroidal epithelial Z310 cells
Z310 cells created by Dr. Wei Zheng is an immortalized rat choroidal epithelial cell line
(Zheng and Zhao, 2002). Cells were cultured as previously described (Zheng and Zhao,
2002, Shi et al., 2008b). In brief, the cells were maintained in DMEM medium
supplemented with 10% fetal bovine serum (FBS), 10ng/mL epidermal growth factor (EGF),
100 U/mL of penicillin, 100 mg/mL of streptomycin and 40 mg/mL of gentamycin in a
humidified incubator with 95% air and 5% CO2 at 37°C and passaged twice a week.
Inhibition of LRP1
Z310 cells were pre-incubated with 100 nM recombinant receptor-associated protein (RAP,
EMD Millipore, Billerica, MA) for 1 hr before the Aβ was added into the inner chamber.
The LRP1 siRNA was obtained commercially from Sigma-Aldrich. The sequences of sense
strand: Th-5′ -CCUAUCUUUGAGAUCCGAA-3′ ; antisense strand: Th-5′ -
UUCGGAUCUCAAAGAUAGG-3′ (Behl et al., 2009a). Cells were seeded at a density of
1 × 105 cells/well in a 6-well plate in cell culture medium. After 24 h, the RNA/transfection
system was prepared as described in manufacturer's protocol: 3 μL 10μM siRNA was diluted
in 500 μL opti-MEM I (Invitrogen, Grand Island, NY). 5 μL lipofectamine RNAiMAX
(Invitrogen, Grand Island, NY) was added into the diluted siRNA and incubated for 20 min
at room temperature. Cell culture medium was replaced with 500 μL of the above mixture
along with 2.5 mL of cell culture medium to obtain a total of 3 mL medium/well. The final
concentration of siRNA was 10nM. The solution containing siRNA was mixed gently by
rocking the plate back and forth. Cells were transfected with scrambled siRNA as a negative
control. Cells were grown for an additional 24 h and then cultured in the transwell transport
device. After two days cell culture, Aβ clearance experiment was performed. The
knockdown efficiency was then analyzed by Western blot analysis.
Determination of LRP1 and RAP Levels by Western Blot
Mouse CP and Z310 cells were homogenized (1:10, wt/vol) on ice in RIPA buffer (Sigma–
Aldrich, St. Louis, MO) with protease inhibitor cocktail (Roche, Indianapolis, IN). The
protein concentration was determined by using the Bradford method. The protein extract (10
μg of protein) was loaded onto a 4–12% Bis–Tris gel, electrophoresed, and then transferred
to a nitrocellulose membrane. The blots were probed with antibody directly against LRP1
(1:20000, abcam, San Francisco, CA) or RAP (1:1000, abcam, San Francisco, CA),
followed by a secondary antibody conjugated with horse-radish peroxidase (1:5000) and
visualized by utilizing enhanced chemiluminescence. β-actin was also assayed as loading
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controls by using its antibody (1:1000, cell signaling, Danvers, MA). Band intensities were
quantified and results were reported as a ratio of LRP1 to β-actin (Gu et al., 2011).
Cultures in Transwell transport device
The Transwell transport device is composed of two chambers which are separated by a
porous polyester membrane insert (Costar, Corning, NY). Z310 cells were seeded on this
membrane. The compartment in the insert is defined as the inner chamber. The lower
compartment is defined as outer chamber. The cells possess tight barrier characteristics
when cells are cultured on a permeable membrane (Shi and Zheng, 2005). Aβ was added
into the inner chamber and measured in the outer chamber. Prior to cell seeding on the
porous polyester membrane within the inner chamber, the membrane was pre-coated with
0.01% collagen (Sigma, St. Louis, MO) for 4-5 hrs at room temperature. 200 μL aliquots of
cell suspensions containing 5.0 × 104 cells were added to the inner chamber followed by
addition of 500 μL of the same culture medium into the outer chamber. A cell monolayer
was usually formed 3-5 days after seeding. The media was refreshed every two days after
seeding. The formation of cell monolayer was judged by three criteria: (1) the cells formed a
confluent monolayer without visible spaces between cells under a light microscope; (2) the
height of the culture medium in the inner chamber had to be at least 2 mm higher than that in
the outer chamber for at least 24 hrs; and (3) a constant transepithelial electrical resistance
(TEER) value across the cell layer was obtained (61.3 ±2.62 Ω.cm2) (Shi and Zheng, 2005).
The TEER is a combination of the paracellular and transcellular flux of small inorganic ions
(predominantly Na+ and Cl−) across the monolayer. The latter contribution is commonly
negligible due to the high lipid membrane resistance, but especially for monolayers with
high paracellular tightness it may contribute to the measured TEER value (Fanning et al.,
1999). The TEER value was measured using an epithelial volt-ohmmeter (EVOM, World
Precision Instruments, Sarasota, FL) after culturing in Transwell chambers for at least 2
days. The net value was calculated by subtracting the background value, which was
measured on a collagen-coated, cell free chamber (blank), from the value of cell-seeded
chamber. The cultures that reached confluence were used in the transport studies. 1 μM
Aβ1-40 were added into the inner chamber media and the outer chamber media were
collected at 1 and 3 hrs following 10mg/ml IVIG and/or 100 nM receptor-associated protein
(RAP, EMD Millipore, Billerica, MA) or LRP1 siRNA treatments.
Quantification of Aβ and Aβ antibody by ELISA
Levels of Aβ and Aβ antibody were assayed by sandwich ELISA as described previously
(Gu et al., 2012) (Hyslop and Bender, 2002). Hippocampus and cortex from mouse brain
were extracted with 5 M guanidine buffer. Tissues are homogenized at room temperature
(RT) and nutated overnight at 4°C. Samples were then diluted 1:10 with sample diluted
buffer (1% BSA with 0.05% Tween-20). Plasma, CSF samples, and culture media collected
from out chamber were diluted 1:2 with diluted buffer. Mice samples, media collected from
outer chamber, and the immunodepleted IVIG were processed in ninety-six-well ELISA
plates that had been coated with antibody 266.2 (generous gifts from Eli Lilly, Indianapolis,
IN) to determine Aβ and Aβ 1-40 to determine A antibody. After incubation of plates with
casein buffer (0.25% casein and 0.05% sodium azide in PBS) for 2 hrs, samples were loaded
overnight at 4°C. Biotin-3D6 (generous gifts from Eli Lilly, Indianapolis, IN) or biotin-anti-
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human IgG (Fc specific) (Sigma, St. Louis, Mo) was incubated for 1 hr at room temperature,
followed by horseradish peroxidase for 1 hr. After incubation with tetramethylbenzidine
(TMB, Sigma, St. Louis, MO) the plates were read for absorbance at 450 nm.
Statistical analysis
Statistical analyses of the differences between groups were carried out by a one-way
ANOVA with post hoc comparisons by the Dunnett's test. All data are expressed as mean
±SD. Differences between two means were considered significant when p was equal or less
than 0.05.
Results
IVIG reduced brain levels but increased blood levels of Aβtotal in AβPP transgenic mice
To verify IVIG effect on Aβtotal levels in AβPP transgenic mice, we treated a group of 3
month old AβPP transgenic mice (n=6 per group) by i.v. administration with IVIG or IVIG
w/o anti-Aβ for 2 weeks. ELISA analyses showed that CSF concentrations of Aβtotal in
IVIG-treated mice after two-week treatments were significantly lower than mice treated with
saline (0.16±0.12 ng/ml versus 0.35±0.14 ng/ml, respectively; p<0.05) (Fig. 1A).
Additionally, two week-treatments of IVIG also significantly reduced Aβtotal levels in the
hippocampus (0.03±0.01ng/mg vs. 0.06±0.01ng/mg, p<0.001) and cortex (0.02±0.01ng/mg
vs. 0.04±0.01ng/mg, p<0.05), respectively, as compared to saline-treated mice (Fig. 1C.D).
In contrast, plasma levels of Aβtotal in one week-treated IVIG-treated mice were
significantly increased as compared to saline-treated mice (0.15±0.06 ng/ml versus
0.06±0.03 ng/ml, p<0.05) (Fig.1B). As a control, treatments with IVIG w/o anti-Aβ had
little effect on both CSF and plasma levels of Aβtotal in transgenic mice as compared to
control (Fig.1). We detected human anti-Aβ antibodies in mice after IVIG treatment. The
CSF and plasma levels of human anti-Aβ antibodies were 2.5±3.3 pg/ml and 289.3 ± 41.5
ng/ml. Human anti-Aβ antibodies were not detected in IVIG w/o anti-Aβ treated mice.
CP Levels of LRP1 and RAP in IVIG treated mice
IVIG reduced Aβtotal levels in APP transgenic mice brains may result from IVIG affected
LRP1 and/or RAP levels in the CP. LRP1 and RAP in the CP were determined by Western
blot. Our results demonstrated that there is no difference between CP levels of LRP1 and
RAP in IVIG treated mice with control mice (Fig.2).
Transepithelial electrical resistance (TEER) values of Z310 cells in the in vitro BCB model
To specifically examine the role of the CP in the regulation of Aβ efflux from brain
following treatments of IVIG, we used a well-established in vitro brain barrier epithelial
transport system that had been widely used for BCB studies (Zheng and Zhao, 2002, Shi and
Zheng, 2005, Shi et al., 2008b, Wang et al., 2008). Z310 cells were grown in the transwell
chamber culture system to form a confluent membrane that possessed tight barrier
characteristics as choroid plexus (Shi and Zheng, 2005). The tightness of the barrier between
two chambers were measured by the TEER after a 2 day culture in Transwell chambers and
TEER could reach 63.9±0.85 Ω.cm2 at day 3 and day 4 in this study (Fig. 3A), was
comparable to the 61.3±2.62 Ω.cm2 reported in the previous report (Shi and Zheng, 2005).
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To test whether IVIG and Aβ affect the rigidity of cell monolayer, TEER was measured
before and after IVIG and Aβ treatments. There was little change between treated and
untreated samples (Fig. 3B).
IVIG induced Aβ efflux from inner chamber
1 μ M Aβ1-40 were added into the inner chamber media and the outer media were collected
at 1 and 3 hrs following treatments. This dose regimen was shown to produce a significant
accumulation of Aβ in Z310 cells in our previous studies (Behl et al., 2009a, Behl et al.,
2009b) and in vitro toxicity studies (Shabala et al., 2010). Aβ concentrations in outer
chamber were gradually increased from 0 into 0.28±0.06 ng/ml at 1 hr and 4.2±0.96 ng/ml
at 3 hrs following treatments. Furthermore, addition of IVIG into the outer chamber
markedly increased amounts of Aβ efflux from inner chambers from 0.28±0.06 ng/ml to
2.52±0.22 ng/ml at 1 hr (p<0.001) and 4.2±0.96 ng/ml to 7.61±0.91 ng/ml at 3 hrs (p<0.001)
of treatments (Fig. 4A).
Low Density Lipoprotein Receptor-related Protein (RAP) partially inhibited efflux of Aβ
from inner chamber
We next examined whether LRP1 was involved in Aβ efflux with or without IVIG
induction. 100 nM RAP, an inhibitor of LRP1 or saline, were added into the inner chamber
for 1 hr followed by the addition of 1 μM Aβ . Without IVIG treatments, Aβ concentrations
in outer chamber were dramatically reduced by RAP from 0.28±0.06 ng/ml to 0.02±0.01
ng/ml 1 hr after Aβ treatments and 4.2±0.96 ng/ml to 1.12±0.51 ng/ml 3 hrs after Aβ
treatments (p<0.001). Furthermore, RAP treatments also significantly blocked IVIG-induced
Aβ efflux from inner chambers 1 hr (from 2.52±0.22 ng/ml to 1.77±0.1 ng/ml, p<0.001) and
3 hrs (from 7.61±0.91 ng/ml to 5.41±0.92 ng/ml, p<0.001) (Fig. 4B).
LRP1 knockdown by siRNA partially inhibited efflux of Aβ from inner chamber
To test whether Aβ efflux following IVIG exposure was indeed mediated by LRP1 in the
BCB, we assessed Aβ efflux in vitro BCB model following LRP1 knockdown by siRNA.
The knockdown efficiency was analyzed by Western blot analysis. As shown in data
presented in Fig. 5, introducing LRP1 siRNA to the cells caused a significant reduction of
LRP1 at protein (84.7%) expression levels as compared to the scrambled siRNA controls
(Fig. 5A, B). Following LRP1 knockdown by siRNA, the Z310 cells were then divided into
four groups (Fig. 5C): scrambled siRNA control without IVIG treatment, LRP1 knockdown
control without IVIG treatment, scrambled siRNA control with IVIG treatment, and LRP1
knockdown cells with IVIG exposure. 1 μM Aβ were added into the inner chamber. Aβ
concentrations in outer chamber were quantified as before using ELISA. Without IVIG
treatments, Aβ concentrations in outer chamber were reduced by LRP1 knockdown from
0.28±0.08 ng/ml to 0.02±0.004 ng/ml 1 hr after Aβ added and 4.0±0.31 ng/ml to 1.17±0.38
ng/ml 3 hrs after Aβ added (p<0.05). Furthermore, after LRP1 was knocked down and
followed by IVIG treatment, IVIG-induced Aβ efflux from inner chambers were reduced
from 2.39±0.51 ng/ml to 1.1±0.28 ng/ml after 1 hr Aβ added (p<0.001) and 7.26±1.14 ng/ml
to 2.86±0.86 ng/ml after 3 hrs Aβ added (p<0.001) (Fig. 5C). These results support the
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hypothesis that increased efflux of Aβ may be mediated at least in part by IVIG effect on
LRP1.
Discussion
IVIG has been clinically used to treat a variety of diseases (Fabian, 1980) and currently, at
least two clinical trials are performed to examine whether IVIG could be used to treat AD.
(Dodel et al., 2002, Neff et al., 2008, Relkin et al., 2009, Dodel et al., 2010). We have
identified anti-Aβ autoantibodies (IgG) in human serum and CSF that may act in an
immune-mediated Aβ clearance pathway (Du et al., 2001, Dodel et al., 2002). Our early
report demonstrated that treatments with IVIG dramatically increased serum levels of Aβ
and significantly lowered CSF levels of Aβ in AD and Multiple Sclerosis patients, possibly
by facilitating the transport of Aβ from the CSF to the serum by its contained anti-Aβ
autoantibodies (Dodel et al., 2002). However, the molecular mechanism underlying IVIG-
induced efflux of Aβ from brain remains unknown. The studies presented in this report took
the advantage of the AβPP transgenic mice, which specifically overexpress Aβ in brain.
Similar to our human studies, mouse data clearly show that after one week treatment with
IVIG containing Aβ autoantibodies, the plasma level of Aβtotal was dramatically higher in
IVIG-treated mice than the saline-treated and IVIG w/o anti-Aβ -treated mice. In contrast,
two weeks of IVIG treatments significantly decreased brain and CSF levels of Aβtotal. The
activities of anti- Aβ in the IVIG and IVIG without anti-Aβ antibodies were detected by
ELISA (Dodel et al., 2002, Du et al., 2003). Naturally occurring antibodies directed against-
amyloid were detected in IVIG. There was a strong signal in IVIG, however, no signal
detected in the IVIG without anti-Aβ antibodies. There was little difference in levels of Aβ
between IVIG w/o anti-Aβ group and saline-treated group, suggesting that Aβ
autoantibodies in IVIG may play a key role in inducing efflux of Aβ from the brain into
blood.
Since the BCB is a major mechanism mediating efflux of molecules from CSF to blood, we
used an established in vitro BCB model (Zheng and Zhao, 2002, Shi and Zheng, 2005, Shi et
al., 2008a) to investigate if and how the BCB was involved in IVIG-induced Aβ
mobilization from brain. Additionally, as LRP1 was reported to possibly contribute to the
regulation of Aβ mobilization in the BCB, we used RAP, a specific LRP1 receptor
antagonist, to further confirm the role of the BCB in Aβ efflux. It was reported that RAP
could bind Aβ at above 500 nM (Kanekiyo and Bu, 2009), therefore in this study, we used
100 nM at which RAP was demonstrated to show little binding affinity to Aβ and still could
significantly block LRP1 function (Shakibaei and Frevert, 1996, Hayashi et al., 2009). As
expected, RAP significantly blocked both basal and IVIG-induced Aβ efflux from inner to
outer chambers. For further confirmation, we performed LRP1 knockdown experiments by
using LRP1 siRNA. The results revealed that inhibition of LRP1 expression significantly
reduced basal and IVIG-induced Aβ efflux. These results suggest that LRP1 should play an
important role in regulating Aβ mobilization in this in vitro BCB model. Results reveal that
IVIG did induce Aβ efflux through the LRP1 receptor in BCB cells. Our data suggests that
the choroid plexus played an important role in removing Aβ from the brain during IVIG
treatments and LRP1 in the BCB was specifically involved at least partially, if not
completely, in this process. Interestingly enough, two AD risk factors, apolipoprotein E and
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alpha2-macroglobulin, are agonists for LRP1 receptor and they may affect IVIG- and other
anti-Aβ antibody-involved therapy.
In our previous study, we found that Aβ autoantibodies in IVIG were mainly present in the
blood after i.v. injection (Bacher et al., 2009). Similar to studies using Aβ-antibody 266
(DeMattos RB et al., 2002), Aβ autoantibodies in IVIG induced Aβ efflux across the CP
from brains into bloods also possibly by the sink mechanism. Additionally, as suggested by
Yamada et al who reported that only soluble free Aβ , not the 266 antibody complexed with
Aβ might move throung the LRP1 in the CP (Yamada et al., 2009), Aβ complexed with
IVIG in peripheral also prevented transport of Aβ back into the brain that could further
enhace Aβ efflex. Furthermore, we found that CP levels of both LRP1 and RAP were not
affected by in vivo IVIG treatments indicating that binding between IVIG and Aβ in
peripheral might be the major force to induce Aβ efflux out of brains.
It should be noted that blockade of LRP1 only partially inhibited Aβ efflux across the BCB
indicating other transport mechanisms may also be involved in IVIG-induced Aβ efflux. P-
glycoprotein (P-gp), an ATP-driven efflux transporter in the CP, was reported to be involved
in Aβ clearance from the brain (Hartz et al., 2010, Pascale et al., 2011). Additionally, there
are other receptors that help transport Aβ from the CSF into the CP epithelium, such as the
RAGE and the low density lipoprotein receptor-related protein 2 (LRP-2) (Pascale et al.,
2011). Both receptors were localized in the CP and linked to Aβ transport form CSF into the
CP cells (Maslinska et al., 2011, Pascale et al., 2011) (Hammad et al., 1997). Therefore,
further studies regarding on roles of other transporters/receptors in IVIG-induced Aβ efflux
are necessary.
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Highlights
• IVIG reduces brain Aβ levels.
• IVIG induces Aβ efflux through the in-vitro BCB membrane.
• RAP and LRP1 siRNA significantly inhibits Aβ efflux.
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Fig. 1.
IVIG treatment decreased brain levels but increased plasma level of Aβtotal. 3 month old
AβPP transgenic mice received i.v. administration of 0.5 mg/kg as IVIG or IVIG w/o anti-
Aβ weekly for 2 weeks. CSF (A), plasma (B), hippocampus (C), and cortex (D), levels of
Aβtotal in control, IVIG-treated, and IVIG that anti-Aβ autoantibodies has been removed
(IVIG w/o anti-Aβ) groups were determined by ELISA. Data represent mean ± SD, n=6. *:
p<0.05, ***: p<0.001.
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Fig. 2.
IVIG treatment didn't affect CP levels of LRP1 and RAP. 3 month old AβPP transgenic
mice received i.v. administration of 0.5 mg/kg as IVIG or IVIG w/o anti-Aβ . After 24
hours, mouse CPs were collected and CP levels of LRP1 and RAP were measured by
Western blot analysis. Data represent mean ± SD, n=3.
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Fig. 3.
Transepithelial electrical resistance (TEER) values of Z310 cells in the in vitro BCB model.
TEER values across the transwell chamber culture system were determined from day 2 to
day 4. TEER values reached 63.9±0.85 Ω.cm2 on day 3 (A). Before and after 3 hrs
incubation with Aβ , TEER values were measured and no difference detected (B). Data
represent mean ± SD of three independent experiments, n = 3.
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Fig. 4.
Media in outer chambers were added with or without 10mg/ml IVIG or IVIG w/o anti-Aβ
for 1 to 3 hrs after addition of 1uM Aβ into inner chambers. IVIG increases Aβ efflux from
inner chambers (A). Treatment of inner chambers with RAP (the LRP1 inhibitor, 100 nM)
significantly inhibited Aβ efflux and IVIG-stimulated Aβ efflux through the formed
confluent layer of Z310 cells (B). Aβ in outer chamber media was quantified by ELISA
method. Data represent mean ± SD of three independent experiments, n=5. *: p<0.05, **:
p<0.01, ***: p<0.001.
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Fig.5.
LRP1 knocked down in Z310 cell by using siRNA. The knockdown efficiency was analyzed
by Western blot analysis. Introducing LRP1 siRNA to the cells caused a significant
reduction of LRP1 at protein (84.7%) expression levels as compared to the scrambled
siRNA controls (A, B). Media in outer chambers were added with or without 10mg/ml IVIG
for 1 to 3 hrs after addition of 1uM Aβ into inner chambers. LRP1 knockdown by using
siRNA decreased Aβ efflux and IVIG-stimulated Aβ efflux through the formed confluent
layer of Z310 cells compared with scrambled siRNA controls (C). Aβ in outer chamber
media was quantified by ELISA method. Control: scrambled siRNA without IVIG
treatment, LRP1 (-): LRP1 knockdown without IVIG treatment, IVIG: scrambled siRNA
with IVIG treatment, IVIG+LRP1 (-): LRP1 knockdown cells with IVIG exposure. Data
represent mean ± SD of three independent experiments, n=3. *: p<0.05, ***: p<0.001.
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